Stock Track | Teva Pharmaceutical Soars 5.41% in Pre-Market on Strong Q1 Earnings Beat and Emalex Acquisition

Stock Track

Apr 29

Teva Pharmaceutical Industries Ltd. (TEVA) surged 5.41% in pre-market trading on Wednesday, driven by the company's better-than-expected first-quarter 2026 financial results and the announcement of a strategic acquisition.

The pharmaceutical giant reported adjusted earnings per share of $0.53 for Q1 2026, surpassing analyst estimates of $0.48. Revenue reached $3.982 billion, exceeding expectations of $3.810 billion and representing a 2.34% increase year-over-year. The strong performance was attributed to growth in key innovative products including AUSTEDO, AJOVY, and UZEDY, which collectively grew by 41% year-over-year.

Additionally, Teva announced a definitive agreement to acquire Emalex Biosciences for $700 million, adding a first-in-class therapy for Tourette syndrome to its neuroscience pipeline. The company maintained its 2026 business outlook while updating it to reflect the Emalex transaction, demonstrating confidence in its continued growth trajectory under its "Pivot to Growth" strategy.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1190868944"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1190868944\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1190868944?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-29 19:12","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1190868944","market":"us","top_or_hot":-1,"title":"Stock Track | Teva Pharmaceutical Soars 5.41% in Pre-Market on Strong Q1 Earnings Beat and Emalex Acquisition","media":"Stock Track","content":"<p>Teva Pharmaceutical Industries Ltd. (TEVA) surged 5.41% in pre-market trading on Wednesday, driven by the company's better-than-expected first-quarter 2026 financial results and the announcement of a strategic acquisition.</p><p>The pharmaceutical giant reported adjusted earnings per share of $0.53 for Q1 2026, surpassing analyst estimates of $0.48. Revenue reached $3.982 billion, exceeding expectations of $3.810 billion and representing a 2.34% increase year-over-year. The strong performance was attributed to growth in key innovative products including AUSTEDO, AJOVY, and UZEDY, which collectively grew by 41% year-over-year.</p><p>Additionally, Teva announced a definitive agreement to acquire Emalex Biosciences for $700 million, adding a first-in-class therapy for Tourette syndrome to its neuroscience pipeline. The company maintained its 2026 business outlook while updating it to reflect the Emalex transaction, demonstrating confidence in its continued growth trajectory under its \"Pivot to Growth\" strategy.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Teva Pharmaceutical Soars 5.41% in Pre-Market on Strong Q1 Earnings Beat and Emalex Acquisition</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Teva Pharmaceutical Soars 5.41% in Pre-Market on Strong Q1 Earnings Beat and Emalex Acquisition\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-04-29 19:12</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Teva Pharmaceutical Industries Ltd. (TEVA) surged 5.41% in pre-market trading on Wednesday, driven by the company's better-than-expected first-quarter 2026 financial results and the announcement of a strategic acquisition.</p><p>The pharmaceutical giant reported adjusted earnings per share of $0.53 for Q1 2026, surpassing analyst estimates of $0.48. Revenue reached $3.982 billion, exceeding expectations of $3.810 billion and representing a 2.34% increase year-over-year. The strong performance was attributed to growth in key innovative products including AUSTEDO, AJOVY, and UZEDY, which collectively grew by 41% year-over-year.</p><p>Additionally, Teva announced a definitive agreement to acquire Emalex Biosciences for $700 million, adding a first-in-class therapy for Tourette syndrome to its neuroscience pipeline. The company maintained its 2026 business outlook while updating it to reflect the Emalex transaction, demonstrating confidence in its continued growth trajectory under its \"Pivot to Growth\" strategy.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"TEVA","symbol_name":"梯瓦制药","start_time":0,"source_url":"","article_id":"1190868944","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1190868944","pubTimestamp":1777461164,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Teva Pharmaceutical Industries Ltd. (TEVA) surged 5.41% in pre-market trading on Wednesday, driven by the company's better-than-expected first-quarter 2026 financial results and the announcement of a...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"TEVA":"梯瓦制药"},"translate_title":"个股追踪|梯瓦制药盘前大涨5.41%因Q1盈利强劲超预期及收购Emalex","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TEVA":1},"content_text":"Teva Pharmaceutical Industries Ltd. (TEVA) surged 5.41% in pre-market trading on Wednesday, driven by the company's better-than-expected first-quarter 2026 financial results and the announcement of a strategic acquisition.The pharmaceutical giant reported adjusted earnings per share of $0.53 for Q1 2026, surpassing analyst estimates of $0.48. Revenue reached $3.982 billion, exceeding expectations of $3.810 billion and representing a 2.34% increase year-over-year. The strong performance was attributed to growth in key innovative products including AUSTEDO, AJOVY, and UZEDY, which collectively grew by 41% year-over-year.Additionally, Teva announced a definitive agreement to acquire Emalex Biosciences for $700 million, adding a first-in-class therapy for Tourette syndrome to its neuroscience pipeline. The company maintained its 2026 business outlook while updating it to reflect the Emalex transaction, demonstrating confidence in its continued growth trajectory under its \"Pivot to Growth\" strategy.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}